<DOC>
	<DOCNO>NCT02823626</DOCNO>
	<brief_summary>Primary Aims 1 . Evaluate safety high-dose spironolactone combination patiromer acute decompensated heart failure patient . 2 . Evaluate efficacy high-dose spironolactone combination patiromer cause volume loss symptom relief patient ADHF treat high-dose spironolactone . Secondary Aims 1 : Evaluate effect high-dose spironolactone urinary sodium excretion renal function .</brief_summary>
	<brief_title>High-dose Aldosterone Antagonist Acute Decompensated Heart Failure</brief_title>
	<detailed_description>Step-by-Step Methods : Pre-screening : Patients meet inclusion exclusion criterion approach participate study . Informed consent take time . These patient receive intravenous loop diuretic per discretion treat physician closely follow weight loss symptom relief . Screening : The patient n't respond measure symptom relief &lt; 0.5 kg weight loss/day 1 . Despite furosemide ≥ 160 mg IV total daily dose equivalent dose torsemide bumetanide . ( 1 mg bumetanide = 10 mg torsemide = 20 mg furosemide ) . OR 2 . After 48 hour irrespective diuretic dose . consider study intervention . Patients participate pre-screening phase respond adequately furosemide &gt; 160 mg iv daily dose directly enrol active intervention part study . Intervention ( High-Dose Spironolactone + Patiromer ) : Patients initiate spironolactone 100 mg orally daily along patiromer 8.4 gm orally ( serum K &gt; 4.3 meq/L ) . The dose loop diuretic stay rest study period . On day 2 , dose spironolactone titrate 200 mg orally day depend diuretic response lab result . Serum potassium monitor twice day . The dose patiromer increase 16.8 gm patient potassium level exceed 5.5 meq/L ; hold serum K &lt; 4.3 mEq/L . Treatment continue till patient achieve euvolemia get discharge . Euvolemia define resolution symptom sign volume overload . Patients follow till achievement euvolemia discharge . Daily assessment do symptom , sign volume overload include shortness breath , orthopnea , paroxysmal nocturnal dyspnea , abdominal bloating , low extremity edema , JVD , body weight change . Serum chemistry assess twice day urine electrolytes day . Neurohormonal analysis do pre-screening , initiation active intervention end study duration . Primary Safety Endpoints : 1 . Incidence hyperkalemia define serum K &gt; 5.5 meq/day . 2 . Renal function : assessed daily serum creatinine Primary Efficacy Endpoints : 1 . Weight loss : use calibrate scale every day hospital gown . 2 . Symptom relief : assess use 5-point Likert scale describe magnitude shortness breath patient supine position .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . More than18 year old 2 . Hospitalized history chronic heart failure least one symptom ( dyspnea , orthopnea edema ) one sign ( rale , peripheral edema , ascites , radiographic pulmonary edema pleural effusion ) 3 . Use loop diuretic 4 . Women child bear age negative urine pregnancy test 1 . Acute coronary syndrome 2 . Patients baseline eGFR &lt; 30 ml/min MDRD equation 3 . Baseline potassium concentration ≥ 5.5 mEq/L 4 . Requirement intravenous vasodilator inotropic agent 5 . Systemic infection 6 . Patients concomitant endstage liver disease 7 . Hemodynamically significant uncorrected valvular disease 8 . Patients pulmonary embolism 9 . Patients high output heart failure 10 . Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>